The treatment is applied in clinical settings that require long-term, supportive care for plaque psoriasis (Psoriasis Vulgaris). This treatment is considered relevant for managing conditions that include Psoriasis Vulgaris (plaque psoriasis) and scalp psoriasis of mild-to-moderate severity. It is generally used to manage groups of symptoms that cluster into persistent, raised lesions and may provide support that helps ease the overall symptom load, contributing to functional stability. The medication is intended to assist with managing symptoms, particularly the excessive skin scaling and the thickening and elevation of plaques. This is relevant in situations where symptoms create noticeable interference, contributing to general comfort during symptomatic periods. It is commonly used across conditions characterized by localized manifestations on the body, limbs, and hair-bearing areas, and is used to help ease discomfort.

“The therapeutic benefit is aligned with providing support during difficult episodes, assisting with the management of noticeable physical symptoms.”

Therapeutic Summary

Quick Fact	Focuses on
Key Condition	Plaque Psoriasis (Psoriasis Vulgaris)
Key Symptoms	Scaling, Plaque Thickness, Redness
Context of Use	Localized, Mild-to-Moderate Lesions, Scalp Psoriasis

Who Can and Cannot Use Дайвонекс (Calcipotriene)

The eligibility for using Дайвонекс (Calcipotriene) is strictly defined by regulatory authorities based on age, underlying health, and physiological state. The medicine is indicated for use in adults with plaque psoriasis. Use is not recommended for children and adolescents under 18 years because safety and effectiveness in the pediatric population have not been established.

Contraindications and Restrictions

Use is contraindicated in patients with a history of hypersensitivity to the active ingredient or excipients. Absolute prohibitions also apply to individuals with demonstrated hypercalcemia or other disorders of calcium metabolism and those with evidence of vitamin D toxicity.

European regulatory labeling contraindicates the medicine in patients with severe renal insufficiency or severe hepatic disorders. The product should not be used on the face and must be avoided in unstable forms of psoriasis, such as erythrodermic or pustular psoriasis.

For women, the medicine is classified as Pregnancy Category C (US FDA), meaning use is conditional on the potential benefit. Caution should be exercised during lactation, and the medicine should not be applied directly to the breast while breastfeeding.

The official regulatory documents for Дайвонекс (Calcipotriene) define its interaction profile primarily through its function as a topical Vitamin D analogue. This classification results in an additive pharmacodynamic effect that creates a risk of elevated calcium levels in the blood, officially termed hypercalcaemia.

Documented Drug and Substance Interactions

Due to this documented risk, co-administration with other topical or systemic Vitamin D analogues or with high-dose calcium or Vitamin D supplements must be considered, as these increase the systemic calcium burden. The medicine is contraindicated in patients who already have documented Hypercalcaemia or evidence of Vitamin D toxicity.

Administration and Environmental Restrictions

The prescribing information details specific constraints on administration. The product must not be physically mixed with other medicinal products. Regarding environmental exposure, official labeling advises patients to limit or avoid excessive exposure to natural or artificial sunlight (UV radiation) during the period of use.

Metabolic Profile and Special Populations

Some regulatory documents state that no formal drug-drug interaction studies were conducted to evaluate the metabolic profile of topical Calcipotriene, including its effects on CYP enzymes or drug transporters. Use is restricted in patients with severe renal or hepatic impairment, a population-specific consideration due to potential issues with clearance and the heightened risk of systemic effects.

The mechanism of Calcipotriene is defined by its selective action as an agonist of the nuclear Vitamin D Receptor (VDR), a transcription factor found in keratinocytes and local immune cells. Upon binding, the VDR forms a heterodimer with the Retinoid X Receptor (RXR), which then binds to DNA to initiate a genomic mechanism that regulates gene expression.

In keratinocytes, this transcriptional modulation results in the inhibition of hyper-accelerated growth and the promotion of terminal differentiation. This mechanistic effect influences epidermal cell kinetics, shifting the cellular balance toward maturation. Concurrently, in local T-lymphocytes, VDR activation modulates immune signaling and reduces the local release of pro-inflammatory cytokines, resulting in suppressed T-lymphocyte activity.

Because the mechanism relies on genomic transcription and subsequent cellular changes, a delayed onset of physiological effect is inherent to this process. Calcipotriene is also chemically modified to exhibit a reduced affinity for the VDR pathways governing systemic mineral homeostasis compared to the natural hormone.

Official Administration Guidelines for Calcipotriol

Дайвонекс (Calcipotriol) is a vitamin D analogue preparation authorized for topical use only as an ointment, cream, or scalp solution, typically at a strength of 50 micrograms per gram/mL. The primary protocol for administration involves applying a thin layer of the preparation directly to the affected psoriatic lesions.

---

Dosing and Frequency

Application is generally recommended once or twice daily. While some regimens initially recommend twice-daily application, the frequency may be reduced to once daily for maintenance, depending on the response, as indicated in the product literature.

Population	Maximum Official Weekly Dose
Adults	100 grams per week (5 mg of calcipotriol total)
Adolescents (12+ years)	75 grams per week
Children (6–12 years)	50 grams per week

When different calcipotriol monotherapy forms are used concurrently, the total weekly amount of active ingredient from all preparations must not exceed the specified maximum dose for the age group. The official duration of use varies, but the maximum treatment course for children (6–17 years) is typically 8 weeks.

---

Procedural Constraints

Standard guidelines specify that application must be avoided on the face, eyes, lips, and areas of thin skin, such as skin folds. Furthermore, the preparation should not be used under occlusive dressings or bandages. Patients must wash their hands thoroughly immediately after applying the medicine to prevent accidental transfer to sensitive areas. The use of Calcipotriol is also advised to be avoided in patients with severe hepatic or renal impairment due to lack of established safety data.

Дайвонекс (Calcipotriol): Recent Clinical Evidence

Clinical research on calcipotriol (known by the brand name Дайвонекс) primarily focuses on its use for treating plaque psoriasis. Calcipotriol is a synthetic derivative of Vitamin D and is often studied alone or in combination with topical corticosteroids, such as betamethasone.

---

Monotherapy and Combination Study Outcomes

• Monotherapy: Controlled trials evaluating calcipotriol cream have noted observations of improvement in the signs and symptoms of psoriasis, typically beginning after two weeks of use. Trials lasting eight weeks have reported that a portion of patients showed at least marked improvement, though complete clearing was less frequently observed.

• Combination Therapy: Numerous studies, including systematic reviews of randomized controlled trials, have compared calcipotriol used alone versus its fixed-dose combination with a potent topical corticosteroid. Evidence suggests that the combination of calcipotriol and a corticosteroid is associated with a greater reduction in overall psoriasis severity scores compared to either agent used as a monotherapy. This combination approach is often used as a first-line topical treatment for mild-to-moderate plaque psoriasis.

---

Safety and Tolerability Observations

Observed Side Effects in Trials:

Observation	Frequency in Controlled Trials (Calcipotriol Cream)
Skin irritation	Approximately 10–15%
Rash, pruritus (itching), dermatitis	1–10%
Worsening of psoriasis	1–10%

In clinical studies, the most common observations of adverse effects included mild and transient irritation, often at the application site or in the surrounding skin. A rare, but recognized, effect of topical calcipotriol is a temporary and reversible elevation of serum calcium (hypercalcemia), typically observed when excessive amounts are applied or when used on large body surface areas. Long-term studies evaluating topical calcipotriol in combination with betamethasone have been conducted for up to 52 weeks and noted that the safety observations were consistent with those seen in shorter trials. No significant differences in reported adverse events have been observed between subjects over 65 years old and those under 65 years old in trials.

Key Studies & References NICE Guideline NG163: Psoriasis: assessment and management

Common questions about Дайвонекс (FAQ)

Q: Дайвонекс — это гормональный препарат или нет?

The active ingredient in Дайвонекс, calcipotriol, is a Vitamin D analogue (a synthetic derivative of the active form of Vitamin D). Official product information confirms that calcipotriol itself is not classified as a corticosteroid, which are the drugs commonly referred to as topical steroids or hormonal medicines. Its mechanism is focused on regulating skin cell growth.

Q: Что делать, если Дайвонекс вызвал сильное жжение?

A burning or stinging sensation is a reported side effect. Regulatory sources indicate that any adverse reactions should be reported to the prescribing physician for guidance. If symptoms are severe, consulting a physician is necessary to determine if temporary discontinuation of the medicine is appropriate.

Q: Как долго можно использовать Дайвонекс без перерыва?

The officially recommended treatment period can vary depending on the specific formulation being used. For monotherapy, this period generally ranges from up to 4 weeks for the ointment to up to 8 weeks for the cream or solution. The final duration of use must be determined by the treating physician based on the patient's response and the product information for the specific form being used.

Q: Что написано в официальных документах о безопасности Дайвонекса при длительном использовании?

Official warnings indicate that using the medicine for too long, applying it over very large areas, or exceeding the maximum recommended weekly dose (such as 100 grams for adults) may increase the risk of systemic absorption. This can potentially lead to a temporary and reversible elevation of calcium levels in the blood, known as hypercalcemia. The official labels state that the effects on calcium metabolism for treatment periods longer than those studied are not established.

Q: Дайвонекс лечит псориаз или только снимает симптомы?

The medicine is officially indicated for the topical treatment of plaque psoriasis. Its mechanism of action helps to regulate the abnormal production and growth cycle of skin cells characteristic of the condition. Official documents describe the medicine’s purpose as helping to control the signs and symptoms of the disease, rather than providing a cure.

Q: Правда ли, что Дайвонекс используют при витилиго?

According to regulatory documentation, this medicine is officially indicated for the topical treatment of plaque psoriasis. Use for other conditions, such as vitiligo, is not included in the medicine's official labeling or approved indications.

Q: Может ли Дайвонекс вызывать сухость кожи?

Yes, regulatory documents list dryness of the skin among the possible reported side effects. Other common skin reactions include irritation, a burning sensation, and redness at the site of application.

Q: Что делать, если случайно проглотил небольшое количество Дайвонекса?

This medicine is strictly for external use only. In the event any amount is accidentally ingested, immediate contact with a doctor or a poison control center is advised.

Q: Есть ли ограничения по питанию при лечении Дайвонексом?

The medicine is not associated with general dietary restrictions. However, because the drug affects calcium metabolism, official guidelines contraindicate the use of this medicine in individuals who have a disorder of calcium metabolism or who are concurrently using high-dose calcium or Vitamin D supplements.

Q: Можно ли использовать косметику или парфюмерию на коже, обработанной Дайвонексом?

Official labeling states that cosmetics or other non-medicinal skin care products should not be applied to the treated areas. The application of other topical products requires specific direction from a prescribing physician.

Q: Действует ли Дайвонекс, если псориаз на голове под волосами?

Yes, the medicine is indicated for the topical treatment of scalp psoriasis. For treatment in hair-bearing areas, specific formulations such as the solution, gel, or foam are approved and typically recommended.

Q: В чем разница между кремом и мазью Дайвонекс?

The different forms are primarily distinguished by their pharmaceutical vehicle, or base. For instance, the ointment typically has a greasier base, while the cream has an aqueous (water-based) base. This difference allows the physician to select the best formulation for various skin surfaces, skin types, and locations.

Q: Применяется ли Дайвонекс при экземе?

According to regulatory documentation, this medicine is officially indicated for the topical treatment of plaque psoriasis. Use for other conditions, such as eczema, is not included in the medicine's official labeling or approved indications.

Q: В каких странах Дайвонекс разрешен к применению?

The active ingredient (Calcipotriol) is approved for use in many regions globally. Key regulatory bodies that have approved its use include the United States (FDA), the European Union (EMA), Canada (Health Canada), and Australia (TGA).

Q: Может ли Дайвонекс взаимодействовать с биологическими добавками?

Official warnings emphasize a contraindication with the use of high-dose Vitamin D or calcium supplements due to the risk of elevated calcium levels in the blood. There is no specific formal information regarding interaction with all other types of biological supplements listed on the regulatory label.

How to Store and Dispose of Daivonex (Calcipotriene)

The storage of Daivonex is strictly defined by regulatory documents to maintain product stability and safety.

Storage Requirements

Condition	Regulatory Mandate
Temperature	Store at controlled room temperature (15 C to 25 C).
Handling	Do not freeze. Protect from light/sunlight.
Container	Preserve in well-closed containers.
Child Safety	Keep out of the sight and reach of children.
Stability	Discard product (for some forms) within six months after first opening.

Disposal Requirements

Unused or expired Daivonex must not be disposed of in household waste or wastewater. The product should be returned to a pharmacist or disposed of according to local, regional, and national regulations for pharmaceutical waste.